Case File
efta-01898487DOJ Data Set 10OtherEFTA01898487
Date
Unknown
Source
DOJ Data Set 10
Reference
efta-01898487
Pages
2
Persons
0
Integrity
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
To:
Jeffrey EpsteinUeeyacationagmail.comj
From:
McGraw, Thomas
Sent
Tue 3/19/2013 4:17:32 PM
Subject: RE:
Assuming first that the partnership, the option contract & capital account positions/values are
respected, then I think an option written that deeply in the money (in return for the economic interest of
preferred cash flow on the units) would raise issues not only as to sale of the art for income tax purposes
depending on capital account provisions & subsequent distributions out of the partnership but also as to
a sale for NY sales tax purposes which as I'm sure you are aware is a rather liberal definition in NY
including precedents on various conditional sales transactions
IRS Circular 230 Disclosure:
JPMorgan Chase & Co. and its affiliates do not provide tax advice. Accordingly, any discussion of
U.S. tax matters contained herein (including any attachments) is not intended or written to be
used, and cannot be used, in connection with the promotion, marketing or recommendation by
anyone unoffiliated with JPMorgan Chase & Co. of any of the matters addressed herein or for the
purpose of avoiding U.S. tax-related penalties.
From: Jeffrey Epstein [mailto:[email protected])
Sent: Monday, March 18, 2013 2:46 PM
To: McGraw, Thomas
Subject:
if i could seperate title from value, it seems to me easy to exchange the value in my art for the
partnership interest. llc with two classes one holds title. ( vote ) ,the other full value, if i
contributed an option at 50 million for the value, currently at 2 billion , I might have a disguised
sale purpose for federal , grantor trust no issue, but i can't imaginge a disguised sales tax ?
The information contained in this communication is
confidential, may be attorney-client privileged, may
constitute inside information, and is intended only for
the use of the addressee. It is the property of
Jeffrey Epstein
Unauthorized use, disclosure or copying of this
communication or any part thereof is strictly prohibited
and may be unlawful. If you have received this
EFTA_R1_00325791
EFTA01898487
communication in error, please notify us immediately by
return e-mail or by e-mail to [email protected], and
destroy this communication and all copies thereof,
including all attachments. copyright -all rights reserved
EFTA_R1_00325792
EFTA01898488
Technical Artifacts (1)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Email
[email protected]Related Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 11OtherUnknown
EFTA02367961
1p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.